NYSE:ZBHMedical Equipment
Should Zimmer Biomet’s Solid Hip and Knee Demand Amid Muted Growth Require Action From ZBH Investors?
Zimmer Biomet’s recently reported second-quarter results highlighted ongoing strength in its hip triple-play and knee portfolios, even as analysts reassessed the company’s muted revenue growth and modest 4.2% return on capital in light of its long operating history and global scale.
The key tension now is between solid procedural demand in core orthopedics and growing concern that management has limited avenues for highly profitable expansion.
Next, we’ll explore how this mix of resilient...